Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2011-07-19 Declaration of Voting R…
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filing with the SEC, dated July 15, 2011, reporting the submission of matters to a vote of security holders at the Annual Meeting of Stockholders. It details the voting results on several proposals including election of directors, ratification of auditors, and amendments to stock plans and certificate of incorporation. The content focuses on official results from shareholder votes at a general meeting. The document length is 4594 characters, which is sufficient to contain detailed voting results rather than just an announcement. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2011-07-19 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (an exclusive license agreement) and the issuance of a press release about this agreement. There are no financial statements or detailed financial data presented. The document is an announcement of a significant corporate event rather than a full financial report or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2011-07-14 English
424(B)(3)
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(3) related to the registration of shares for sale by selling stockholders. It includes sections such as Prospectus Summary, Business Overview, Risk Factors, Use of Proceeds, Selling Stockholders, Plan of Distribution, and Description of Common Stock. The document is clearly a registration prospectus for securities offering, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. This type of filing corresponds to a capital/financing update or securities offering document. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). Therefore, the correct classification is CAP with high confidence.
2011-06-16 English
Regulatory Filings 2011
Regulatory Filings
2011-06-16 English
FORM S-3/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-3/A registration statement amendment filed with the SEC by RXi Pharmaceuticals Corporation. It is a registration statement under the Securities Act of 1933, used for registering securities for sale to the public. The document includes a prospectus describing the securities being registered, the selling stockholders, and the plan of distribution. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to securities registration and offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed information about the securities offering, not just an announcement or notice, so it is not RPA or RNS.
2011-06-11 English
FORM 8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 3) filed with the SEC, which is a current report pursuant to the Securities Exchange Act of 1934. It provides updated pro forma financial information related to an acquisition (Apthera, Inc.) and references previous 8-K filings. The document includes unaudited pro forma condensed combined financial information as an exhibit. The length is 3196 characters, which is relatively short and the document primarily serves as an amendment to a previously filed current report, providing updated financial information related to a business acquisition. This type of filing is best classified under Regulatory Filings (RNS) as it is a current report amendment and not a full financial report like an Annual Report or Interim Report. It is not a direct announcement of a merger or acquisition (which would be MA or TAR), but rather an SEC current report amendment with financial data related to acquisition. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2011-06-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.